Vmbook Online ordering

Receptos Inc

Receptos, Inc was a publicly traded biotechnology company that focused on developing therapeutics for the treatment of autoimmune diseases, inflammation and cancer.

The company's lead drug candidate was Ozanimod, which was studied in multiple sclerosis, ulcerative colitis and inflammatory bowel disease. Receptos was acquired by Celgene Corporation in August 2015.

Before its acquisition, Receptos was listed on the NASDAQ stock exchange under the ticker symbol "RCPT."

The company was founded in 2009, and its headquarters were in San Diego, California.

As of March 2015, Receptos had raised approximately $191 million in funding from investors, including a $120 million initial public offering (IPO) in 2013.

In terms of stock performance, Receptos' stock price surged 23.4% to $23.49 on April 14, 2015 after Celgene Corporation reported better-than-expected results for its psoriasis drug contender fedratinib.

Overall, Receptos was a promising biotech company that showed significant potential in developing innovative therapies.

I hope this was resourceful!